Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Nilotinib/ponatinib

Arterial occlusive events: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Abdelmagid MG, et al. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood Cancer Journal 13: No. 1, 2023. Available from: URL: http://doi.org/10.1038/s41408-023-00891-x Abdelmagid MG, et al. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood Cancer Journal 13: No. 1, 2023. Available from: URL: http://​doi.​org/​10.​1038/​s41408-023-00891-x
Metadaten
Titel
Nilotinib/ponatinib
Arterial occlusive events: 4 case reports
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-47655-x

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Oxybutynin

Case report

Multiple drugs

Case report

Aripiprazole